Therefore, suppressing the production of pro-inflammatory cytokines and COX-2 in LPS-induced A549 cells is a representative treatment method applicable to inflammatory symptoms caused by pneumonia. Here, PTGS2 is linked to susceptibility to pneumonia measurement.